Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes.
Amy W KuJason B MuhitchColin A PowersMichael DiehlMinhyung KimDaniel T FisherAnand P ShardaVirginia K ClementsKieran O'LoughlinHans MindermanMichelle N MessmerJing MaJoseph J SkitzkiDouglas A SteeberBruce WalcheckSuzanne Ostrand-RosenbergScott I AbramsSharon S EvansPublished in: eLife (2016)
Myeloid-derived suppressor cells (MDSC) contribute to an immunosuppressive network that drives cancer escape by disabling T cell adaptive immunity. The prevailing view is that MDSC-mediated immunosuppression is restricted to tissues where MDSC co-mingle with T cells. Here we show that splenic or, unexpectedly, blood-borne MDSC execute far-reaching immune suppression by reducing expression of the L-selectin lymph node (LN) homing receptor on naïve T and B cells. MDSC-induced L-selectin loss occurs through a contact-dependent, post-transcriptional mechanism that is independent of the major L-selectin sheddase, ADAM17, but results in significant elevation of circulating L-selectin in tumor-bearing mice. Even moderate deficits in L-selectin expression disrupt T cell trafficking to distant LN. Furthermore, T cells preconditioned by MDSC have diminished responses to subsequent antigen exposure, which in conjunction with reduced trafficking, severely restricts antigen-driven expansion in widely-dispersed LN. These results establish novel mechanisms for MDSC-mediated immunosuppression that have unanticipated implications for systemic cancer immunity.
Keyphrases
- lymph node
- poor prognosis
- papillary thyroid
- traumatic brain injury
- neoadjuvant chemotherapy
- high glucose
- induced apoptosis
- squamous cell carcinoma
- adipose tissue
- drug induced
- metabolic syndrome
- early stage
- squamous cell
- type diabetes
- transcription factor
- cell proliferation
- cell cycle arrest
- signaling pathway
- insulin resistance
- locally advanced